Build a lasting personal brand

VolitionRx Expands Fujifilm Vet Systems Agreement to Develop Feline Cancer Test in Japan

By Burstable Editorial Team•
VolitionRx Limited has expanded its supply agreement with Fujifilm Vet Systems to develop and use its Nu.Q Vet Feline Test in Japan, targeting a feline population of nearly 9 million and building on the success of its canine cancer test.
VolitionRx Expands Fujifilm Vet Systems Agreement to Develop Feline Cancer Test in Japan

VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the expansion of its supply agreement with Fujifilm Vet Systems Co. Ltd. in Japan to include the development and use of its Nu.Q Vet Feline Test. The agreement builds on the July 2024 launch of the Nu.Q Vet Canine Test in Japan, where growing veterinary demand prompted the introduction of an automated version earlier this year.

The expansion follows research demonstrating high accuracy for a prototype feline assay in detecting lymphoma, the most common cancer in cats. Fujifilm plans to conduct an additional study with veterinary oncologists in Japan. Volition said the expanded agreement presents a potential revenue opportunity in Japan, where the feline population approaches 9 million.

The company is continuing product development of the blood-based feline cancer test, with plans to launch it on the Immunodiagnostic Systems (“IDS”) i10 automated analyzer platform. Volition aims to make cancer screening a routine component of annual veterinary wellness examinations, extending its existing canine testing technology to address the need for earlier cancer detection in cats.

For readers tracking the company, detailed market data on VolitionRx Limited (NYSE American: VNRX) is available. The full press release can be viewed at https://ibn.fm/6fgSw.

Volition, a multi-national company focused on advancing the science of epigenetics, is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. More information about Volition is available online.

The announcement was distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.

Burstable Editorial Team

Burstable Editorial Team

@burstable

Burstable News™ is a hosted solution designed to help businesses build an audience and enhance their AIO and SEO press release strategies by automatically providing fresh, unique, and brand-aligned business news content. It eliminates the overhead of engineering, maintenance, and content creation, offering an easy, no-developer-needed implementation that works on any website. The service focuses on boosting site authority with vertically-aligned stories that are guaranteed unique and compliant with Google's E-E-A-T guidelines to keep your site dynamic and engaging.